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Abstract
Background: Tuberous sclerosis complex (TSC) is a genetic disorder with an incidence of 1:6000 live births and
associated with the development of benign tumors in several organs. It is also characterized by high rates of neurological
and neuropsychiatric abnormalities, including epilepsy affecting 70–90% of patients and being one of the major
risk factors of intellectual disability. The first seizures in TSC patients appear usually between the 4th and the
6th months of life. Recent studies have shown the beneficial role of preventative antiepileptic treatment in
TSC patients, with the possibility for improvement of cognitive outcome. Moreover, European recommendations suggest
early introduction of Vigabatrin if ictal discharges occur on EEG recordings, with or without clinical manifestation.
The aim of this study was to define the most useful approach to make the diagnosis of TSC before seizure onset (before
age 4th months), in order to start early EEG monitoring with possible preventative treatment intervention.
Methods: We performed a retrospective review of children who were suspected of having TSC due to single or multiple
cardiac tumors as the first sign of the disease. We analyzed the medical records in terms of conducted clinical tests and
TSC signs, which were observed until the end of the 4th month of age. Subsequently, we described the different clinical
scenarios and recommendations for early diagnosis.
Results: 82/100 children were diagnosed with TSC within the first 4 months of life. Apart from cardiac tumors, the most
frequently observed early TSC signs were subependymal nodules (71/100, 71%), cortical dysplasia (66/100, 66%),
and hypomelanotic macules (35/100, 35%). The most useful clinical studies for early TSC diagnosis were brain
magnetic resonance imaging (MRI), skin examination and echocardiography. Genetic testing was performed in
49/100 of the patients, but the results were obtained within the first 4 months of life in only 3 children.
Conclusions: Early diagnosis of TSC, before seizure onset, is feasible and it is becoming pivotal for epilepsy
management and improvement of cognitive outcome. Early TSC diagnosis is mostly based on clinical signs.
Brain MRI, echocardiography, skin examination and genetic testing should be performed early in every patient
suspected of having TSC.
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Background
Tuberous sclerosis complex (TSC) is a multisystem gen-
etic disorder associated with the development of benign
tumors (hamartomas) in several organs, including heart,
brain, skin, kidney, liver and lungs. The prevalence of
TSC is estimated as 1:6000 live births [1]. The disease is
caused by heterozygous mutations in either TSC1,
located on chromosome 9q34 and encoding hamartin,
or TSC2 located on chromosome 16p13.3 and encoding
tuberin [1, 2]. Hamartin and tuberin form a heterodimer
that suppresses the mTOR pathway, which coordinates
various aspects of cell functioning, including cell growth,
metabolism and proliferation [1]. Overactivation of the
mTOR pathway in TSC patients is responsible for the
development of tumors in different organs [1, 2]. TSC is
the result of a de novo mutation in 2/3 of the affected
people, while is inherited in 1/3 of the patients [1].
TSC2 mutations are more frequent in sporadic cases
and are usually associated with more severe clinical
outcome [1, 2].
In TSC patients hamartomas may develop in various
organs causing different symptoms [1–3]. Moreover, the
clinical presentation differs between pediatric and adult
individuals [3]. Whereas some signs may be observed
even prenatally using antenatal ultrasonography or mag-
netic resonance imaging (MRI), other manifestations ap-
pear with age and are specific for the adult age [1, 3, 4].
Furthermore, disease severity may vary greatly from mild
to severe in patients of the same age, even among family
members [1]. Although the diagnosis of TSC is based
mostly on clinical criteria, the recommendations from
the Tuberous Sclerosis Consensus Conference in 2012
accepted the identification of a pathogenic mutation in
either gene as sufficient to establish the diagnosis [4].
TSC is characterized by high rates of neurological and
neuropsychiatric abnormalities, which represent a major
cause of morbidity [5]. The vast majority of patients
show central nervous system (CNS) manifestations
including epilepsy, cognitive impairment and autism
spectrum disorders [1, 5]. Epilepsy affects 70% to 90% of
patients and is one of the most devastating comorbidi-
ties [1, 3, 6, 7]. Usually the first clinical seizures appear
between the 4th and the 6th month of life [6–10]. How-
ever, the ictal abnormalities on EEG recordings predate
clinical seizures [8, 10–13]. Moreover, the epileptogenic
process begins even earlier during the latent period with
alterations in gene expression, ion channel functions and
synapses transmission [11]. Soon, paroxysmal discharges
on EEG recordings occur, preceding clinical manifesta-
tions, lasting longer and longer, changing morphology,
and finally leading to subtle partial seizures [8, 12].
These events may be easily overlooked by parents, and
seizure onset may be noticed only late, with the begin-
ning of generalized seizures [14].
Different types of seizures may be present and coexist
in the course of TSC. The most destructive are infantile
spasms, which occur in approximately 30–60% of pa-
tients [6, 8, 15]. It is documented that epilepsy, especially
infantile spasms, is one of the major risk factors of cog-
nitive impairment in TSC [6, 9, 10, 16, 17]. Usually chil-
dren with earlier seizure onset present more severe
developmental delay [16–18]. In the prospective study of
Capal et al. on TSC patients the group of children with-
out epilepsy developed better and had lower risk of aut-
ism spectrum behaviors compared to the group who
suffered from seizures [17]. Moreover, earlier onset and
higher seizure frequency, especially before 12 months of
age, were also associated with poorer developmental out-
come and increased risk of autism spectrum disorder
[17]. Overall, the prevalence of cognitive impairment in
TSC is about 40–70%, and more than 1/3 of the patients
are profoundly impaired [6–10]. However, in the light of
recent studies this prognosis may be improved.
Recent reports showed the beneficial role of early anti-
epileptic, or rather antiepileptogenic, intervention in
TSC patients and the possibility for improvement of
cognitive outcome [9, 10]. In our previous study, we
treated with Vigabatrin a group of infants showing par-
oxysmal activity on EEG before the onset of clinical sei-
zures (preventative treatment): that group achieved
better seizure control and had better cognitive outcome
at age 24 months compared to the group who was
treated after clinical seizure onset [10]. Moreover, the
significant number of preventively treated children did
not develop epilepsy, and their EEG recordings - which
were pathological at the beginning - normalized at the
end of the study. The comparative, randomized study of
both therapeutic approaches is currently continuing
within the EPISTOP project [19]. Recent European rec-
ommendations on epilepsy treatment in TSC also sug-
gest the early introduction of Vigabatrin treatment
within 24 months of life if ictal discharges occur on EEG
recordings, with or without clinical manifestation [18].
In the light of the recent studies and recommenda-
tions, it is therefore essential to make a diagnosis of TSC
as soon as possible, in order to allow epileptogenic treat-
ment before seizure onset, with a view to improvement
of clinical outcome.
In this study, we propose the most useful approach to
make the diagnosis of TSC in the newborn period and
early infancy, before age 4 months, which is regarded as
the usual time of clinical seizure onset.
Methods
We performed a retrospective chart review of children
born between 1990 and 2016 who were referred to the
Department of Neurology and Epileptology of The Chil-
dren’s Memorial Health Institute of Warsaw (68 children,
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which represents 20% of TSC population in our centre
born between 1990 and 2016) and to the Child
Neuropsychiatry Unit and Epilepsy Center of the San
Paolo Hospital in Milan (32 children, which repre-
sents 13% of TSC population in our centre born be-
tween 1990 and 2016) with suspicion of TSC due to
single or multiple cardiac tumors.
The study group was divided into three groups: pa-
tients with ‘early diagnosis of TSC’, established until the
end of 16 weeks of age (4 months); patients with ‘late
diagnosis of TSC’, made after 16 weeks of age; and pa-
tients with ‘possible TSC’, in whom the diagnosis was
not certain.
We analyzed the medical records in terms of clinical
tests that were conducted and TSC diagnostic signs that
were observed within age 16 weeks. We applied the
diagnostic criteria according to the recent recommenda-
tions from the Tuberous Sclerosis Consensus Confer-
ence in 2012 [3]. The diagnosis of TSC was confirmed in
children with at least two major criteria or one major
and two minor, or when a pathogenic mutation in either
TSC1 or TSC2 was identified.
We reported the results of the clinical studies per-
formed in our patients within the first 16 weeks of
life. The utility of each particular test in early detec-
tion of TSC was defined as the percentage of studies
conducted in the first 16 weeks of age that demon-
strated diagnostic lesions.
Finally, we divided the group with ‘early TSC diagno-
sis’ into different clinical scenarios with the association
of TSC diagnostic signs observed within the first
16 weeks of age.
The statistical analysis was performed with the STA-
TISTICA 12 software using the Fisher exact test. Values
of P < 0.05 were considered statistically significant.
Results
A group of 100 patients was referred to our clinics due
to single (14% 14/100) or multiple (86%, 86/100) cardiac
tumors (rhabdomyomas) as the first possible presenta-
tion of TSC. The diagnosis of TSC was not confirmed in
5 patients out of 100 (5.0%) either by clinical studies or
by molecular testing (the group of ‘possible TSC’). In 13
cases (13/100, 13.0%) the diagnosis of TSC was made
after age 16 weeks (the group of ‘late TSC diagnosis’).
Eighty-two patients out of 100 (82.0%) - 42 boys (51.2%)
and 40 girls (48.8%) - were defined as the group with
‘early diagnosis of TSC’, as the disease had been con-
firmed before the end of the 16th week of age.
Timing of TSC diagnosis
Cardiac tumors were detected prenatally in 71 individ-
uals (71/100, 71.0%). Subsequently, antenatal brain MRI
was conducted in 30 children (30/71, 42.3%) and
prenatal diagnosis of TSC was confirmed in 20 patients
(20/100, 20.0%) due to pathological lesions (cardiac tu-
mors and subependymal nodules, cortical tubers or sub-
ependymal giant cell astrocytoma). Postnatal diagnosis
of TSC was obtained in 75 patients (75/100, 75.0%). The
age of postnatal diagnosis ranged from 1 day to 9.4 years
(average age: 23.2 ± 67.6 weeks, median age: 4.5 weeks).
The age of postnatal diagnosis ranged from 1 day to
16 weeks (average age: 5.3 ± 4.7 weeks, median age:
3.1 weeks) in the patients with ‘early’ diagnosis, and from
18 weeks to 9.4 years (average age: 2.1 ± 2.6 years, median
age: 1.3 years) in the patients with ‘late’ diagnosis.
Clinical tests
The clinical tests performed before the end of the 16th
week of age were: antenatal or postnatal brain MRI,
transfontanelle ultrasonography (TUS), skin examination
(SE) including examination with Wood’s lamp, abdom-
inal ultrasonography (US) or MRI, ophthalmological
examination (OE) with fundoscopic exam, echocardiog-
raphy, and genetic testing. Table 1 shows the results of
the clinical tests conducted in the study group within
the first 16 weeks of age, the average age of the first and
last examination, and the age when pathological lesions
were detected.
Clinical signs of TSC
Apart from cardiac tumors, the most frequent signs of
TSC observed within the first 16 weeks of age were CNS
lesions (76/100, 76.0%) (mainly subependymal nodules
(71/100, 71.0%) and cortical dysplasia (66/100, 66.0%)),
and hypomelanotic macules (35/100, 35.0%). Table 2
summarizes the diagnostic signs that were present in the
group of ‘early TSC diagnosis’ in the first 16 weeks of
age. Additionally, subependymal giant cell astrocytoma
(SEGA), multiple retinal hamartomas, multiple renal
cysts and retinal achromic patches were also detected in
some children. Nevertheless, none of the patients
showed other major (facial angiofibromas, ungual fibro-
mas, shagreen patch, lymphangioleiomyomatosis, renal
angiomyolipomas) or minor (dental enamel pits, intraoral
fibromas, confetti skin lesions, non-renal hamartomas)
diagnostic criteria of TSC.
Table 3 illustrates the ‘clinical scenarios’, i.e. the associ-
ation of TSC signs observed within the first 16 weeks of
age in the group of ‘early TSC diagnosis’.
Genetic testing
Genetic testing was conducted in 49 out of 100 patients
(49.0%), including 40 (40/49, 81.6%) patients with ‘early
diagnosis of TSC’, 7 (7/49, 14.3%) with ‘late diagnosis of
TSC’, and 2 (2/49, 4.1%) with ‘possible TSC’, respectively.
A summary of molecular testing results is presented in
Table 4. A pathogenic variant was identified in 91.9% of
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examined children (45/49). In 4 patients (4/49, 8.1%) no
causative mutation was detected. However, 2 of those
children were diagnosed with TSC based on clinical
signs. Other 2 patients with undetected mutation have
been included into the group of ‘possible TSC’ as no
other signs of the disease were observed. Only in 3 pa-
tients (3/49, 6.1%), in whom blood samples were col-
lected for genetic test, the results were obtained before
16 weeks of life. Nevertheless, those children had been
already diagnosed with TSC based on clinical signs.
However, according to the recent diagnostic criteria [4],
the disclosure of a pathogenic variant enabled the ‘late’
diagnosis of TSC in 4 children (4/100, 4.0%) in whom
other clinical signs were not present. There was no sig-
nificant difference between the proportion of TSC1 and
TSC2 mutations between the group of ‘early’ and ‘late’
TSC diagnosis (p > 0,05).
The group of ‘late diagnosis’ (diagnosis made after age
16 weeks)
In the group of ‘late diagnosis of TSC’ (13 children), the
clinical tests performed by age 16 weeks were: transfon-
tanelle ultrasonography in 5 (5/13, 38.5%) and brain
MRI in 4 (4/13, 30.8%) cases, abdominal ultrasonography
in 7 (7/13, 53.8%) patients, ophthalmological examination
in 3 children (3/13, 23.1%), skin examination with Wood’s
lamp in 7 cases (7/13, 53.9%), and echocardiography in 13
patients (13/13, 100%). Nevertheless, apart from echocar-
diography, those tests did not reveal any pathological le-
sions. In 4 children (4/13, 30.8%) the diagnosis of TSC
was made based on the identification of a pathogenic mu-
tation. The average age of the molecular diagnosis in these
four patients was 1.3 ± 0.5 years (median age: 1.5 years).
Other 9 (9/13, 69.2%) children were eventually diagnosed
with TSC based on the presence of cardiac tumors and
CNS lesions. The average age of diagnosis in those 9 pa-
tients was 2.4 ± 3.1 years (median age: 0.6 years).
The group of ‘possible TSC’
In the group with not definite TSC diagnosis skin exam-
ination and postnatal brain MRI were conducted in all
cases. Median age of last follow up was 77 weeks for skin
examination and 36.7 weeks for brain MRI. Abdominal
ultrasonography or MRI were performed in 3 patients (3/
5, 60.0%) with median time of the last examination at age
19.3 weeks. Ophthalmological consultation was done in
one child (1/5, 20.0%) at age 17 weeks. Genetic test was
performed in two cases (2/5, 40.0%) at a median age of
Table 2 TSC signs observed within 16 weeks of age in patients with ‘early TSC diagnosis’ (n = 82)
TSC signs Major criteria Minor criteria Pathogenic
CTs SEN CD SEGA HMs MRH MRC RAP TSC1/2
mutation
No. of patients 82 71 66 5 35 5 8 2 3
Per cent % 100% 86.6% 80.5% 6.1% 42.7% 6.1% 9.8% 2.4% 3.7%
CTs cardiac tumors, SEN subependymal nodules, CD cortical dysplasia: includes cortical tubers and white matter migration lines, SEGA subependymal giant cell
astrocytoma, HMs hypomelanotic macules, MRH multiple retinal hamartomas, MRC multiple renal cysts, RAP retinal achromic patch
Table 3 The association of TSC signs within 16 weeks of age in ‘early diagnosed’ children (n = 82)
Major criteria Minor criteria Genetic diagnosis
cardiac tumors At least one CNS lesion
(SEN, cortical dysplasia or SEGA)
HMs multiple retinal
hamartomas
multiple
renal cysts
retinal achromic
patch
TSC1/2 mutation No. of patients (%)
+ + 37 (45.1%)
+ + + 24 (29.3%)
+ + 5 (6.1%)
+ + + + 3 (3.7%)
+ + + 3 (3.7%)
+ + + 3 (3.7%)
+ + + 2 (2.4%)
+ + + + + 1 (1.2%)
+ + + + + 1 (1.2%)
+ + + + 1 (1.2%)
+ + + + 1 (1.2%)
+ + + 1 (1.2%)
CNS central nervous system, SEN subependymal nodules, cortical dysplasia includes cortical tubers and white matter migration lines, SEGA subependymal giant
cell astrocytoma, HMs hypomelanotic macules
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2.4 years, and no pathogenic variants were identified. Fur-
ther follow up was not continued, as the patients were
under the care of other hospitals and outpatient clinics.
Discussion
The aim of this study was to define the most useful ap-
proach to make the diagnosis of TSC before clinical
seizures onset (i.e. before age 4 months) in order to fa-
cilitate early EEG monitoring and possible preventative
antiepileptogenic treatment intervention. Recent studies
showed the beneficial role of this approach in children
younger than age 2 years with improvement of cognitive
outcome and better seizure control [10, 11]. This strat-
egy is currently applied in the multicenter European
Commission project EPISTOP [19]. In the EPISTOP
project, patients with the diagnosis of TSC established
before seizure onset are monitored with EEG every
4 weeks in the first 6 months of life and every 6 weeks
thereafter. The treatment is introduced if ictal discharges
in the EEG recording occur, before clinical seizures [19].
Moreover, recent European recommendations on epi-
lepsy treatment in TSC also suggest early introduction
of Vigabatrin within 24 months of life if ictal discharges
occur, with or without clinical manifestation [18].
However, the early diagnosis of TSC is still a challenge
in the majority of cases as diagnostic workup often be-
gins after seizure onset [20]. Therefore, the aim of this
study was to define a useful approach that especially the
neonatologist and pediatrician can utilize to make the
diagnosis of TSC before seizures onset.
In this study, we selected children in whom the first
sign of TSC was single or multiple cardiac tumors (rhab-
domyomas). Cardiac rhabdomyomas (CRs) are the most
frequent cardiac tumors in children and the earliest de-
tectable sign of TSC [1, 21]. They can be diagnosed from
the 20th gestational week [21]. Although both single and
multiple tumors are associated with TSC [4], the
probability of having the disease increases in patients
with multiple lesions [22, 23]. Tworetzky et al. diagnosed
TSC in 95% of individuals with multiple cardiac tumors
compared to 23% with single ones [22]. Conversely,
the frequency of CRs in TSC patients varies with age
[2, 21, 24]. Overall, about 50% of the patients have
cardiac tumors [21]. However, they are seen in higher
frequency in children younger than 2 years of age
and then they usually regress over time [21].
An additional benefit of early CRs recognition is the
possibility to perform antenatal MRI with ultrafast im-
aging, which, compared to the postnatal study, does not
require maternal or fetal sedation [24–27]. Prenatal
brain MRI is usually performed in the third trimester,
although detection of subependymal nodules (SEN) in
the 21st gestational week has also been reported [26].
Moreover, children diagnosed prenatally have a greater
chance for improved prognosis as prenatal diagnosis of
TSC provides the possibility of personalized pregnancy
management and of referring the pregnant woman and
child to referenced centers, with a view to early imple-
menting optimal management and EEG monitoring. In
our study group prenatal MRI enabled TSC diagnosis in
2/3 of the children (20/30, 66.7%) in whom the test was
performed. Nevertheless, one should keep in mind that
negative results of antenatal MRI do not exclude TSC.
In the remaining 10 children (10/30, 33.3%) with normal
prenatal MRI, 8 patients (8/30, 26.7%) were diagnosed
with TSC after birth due to the disclosure of CNS
lesions in postnatal scans (6 children) or identification of
a pathogenic mutation (2 children). Therefore, postnatal
brain MRI should be performed even when antenatal
MRI does not show abnormalities. As a matter of fact,
postnatal brain MRI was performed within age 16 weeks
in the vast majority of the children in our cohort (83/
100, 83.0%), and it significantly contributed to early TSC
diagnosis (Table 1 and Table 3).
Table 4 Results of genetic testing
Overall The group of ‘early
TSC diagnosis’
The group of ‘late
TSC diagnosis’
The group of
‘possible TSC’
No. of patients in whom the genetic tests was
conducted
49/100 (49.0%) 40/82 (48.8%) 7/13 (53.8%) 2/5 (40.0%)
TSC1 mutation 9 (18.4%) 7 (17.5%) 2 (28.6%) 0 (0.0%)
TSC2 mutation 36 (73.5%) 31 (77.5%) 5 (71.4%) 0 (0.0%)
No mutation identified (NMI) 4 (8.1%) 2 (5.0%) 0 (0.0%) 2 (100%)
Average age of patients when the result was
obtained (years)
4.7 ± 7.2 4.3 ± 6.0 3.5 ± 6.4 2.4 ± 0.0
Median age of patients when the result was
obtained (years) [range]
1.5 1.4 6.4 2.2
[0.1–21.0] [0.1–21.0] [0.4–18.0] [2.0–2.4]
No. of mutations detected by age 16 weeks 3/49 (6.1%) 3/40 (7.5%) 0 0
No. of patients in whom genetic testing
enabled TSC diagnosis
4/100 (4.0%) 0 4/13 (30.8%) 0
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Other major diagnostic criteria of TSC are dermato-
logical findings, with hypomelanotic macules (HMs) be-
ing a major diagnostic criterion of TSC and the most
common dermatological manifestation, present in 90–
98% of patients [1, 3, 4]. Furthermore, as other skin
signs usually appear in older children or adults, HMs are
the earliest detectable skin manifestation and might be
seen even in newborns [1–3, 28]. In our cohort, at least
3 HMs were found early in 1/3 of the patients (35/100,
35.0%) (Table 1). Moreover, in 5 children (5/82, 6.1%), in
the group of ‘early TSC diagnosis’, they considerably
contributed to the diagnosis when other extra-cardiac
manifestations were not present (Table 3). Therefore,
although HMs are not pathognomonic for TSC and
may be observed in other conditions as well as in
healthy individuals [28], they facilitate the early diag-
nosis of the disease.
Detection of ophthalmological changes may also aid
the TSC diagnosis. Diagnostic ophthalmological findings
comprise multiple retinal hamartomas as a major criter-
ion and multiple achromic patches as minor ones [4].
They have been reported in 39–50% of TSC patients and
may be found at any age [1, 29, 30]. In the group of
‘early TSC diagnosis’ we found multiple retinal hamarto-
mas in 5 (5/82, 6.1%) and achromic patches in 2 (2/82,
2.4%) patients. However, these signs were not crucial for
the diagnosis in any case, as other diagnostic criteria
(CRs, CNS lesions or HMs) had been detected earlier.
Renal manifestations of TSC may also contribute to
the diagnosis. They include renal angiomyolipomas
(AMLs), renal cysts and renal carcinoma. The first two
are major and minor diagnostic criteria, respectively [4].
AMLs are present in as many as 80% of patients, but
they usually develop after the third year of age [1–3].
Accordingly, we have not found AMLs in any of our pa-
tients in the first 16 weeks of age. On the other hand,
multiple renal cysts may be present since infancy [1–3].
Moreover, autosomal dominant polycystic kidney disease
(ADPKD) may coexist with TSC as large deletions of
TSC2 may also involve PDK1, whose mutations are re-
sponsible for ADPKD [31]. In our cohort, we found
renal cysts in only 8 patients (8/100, 8.0%). However, as
multiple renal cysts are a minor diagnostic criterion, in
terms of the absence of other minor signs among those
patients, renal cysts were only additional features and
did not decide about the diagnosis.
Since 2012 the identification of a pathogenic mutation
in TSC1 or TSC2 is sufficient for establishing the diag-
nosis [4]. Therefore, DNA testing became a useful diag-
nostic tool. A pathogenic mutation is reported to be
found in 75–90% of TSC patients [32]. This percentage
is considerably increased when full gene coverage and
next generation sequencing (NGS) are used [32]. Genetic
testing results were not obtained early in our study in
the vast majority of patients (46/49, 93.9%) in whom
DNA testing was performed. Nevertheless, the availabil-
ity of molecular testing is improving, and genetic ana-
lyses may significantly contribute to early TSC diagnosis
in the future. In our study identification of the patho-
genic mutation enabled the ‘late’ diagnosis in the ab-
sence of other clinical signs in 4 children (4/100, 4.0%).
Our study shows that early diagnosis of TSC, before
clinical seizure onset, is feasible. In the vast majority of
our patients (82/100, 82.0%) the diagnosis was estab-
lished before the end of the 4th month of life (16 weeks),
which is regarded as the usual time of clinical seizure
onset. Thus in this study the cut-off point between the
groups was 16 weeks (4 months), it need to be acknowl-
edged that epileptogenic process begins even earlier in
TSC patients and clinical seizures are preceded by EEG
abnormalities [8, 10–13]. In our recent study we reported
that regular surveillance EEG and early implementation of
the antiepileptic treatment when paroxymal discharges on
EEG record occur but before clinical seizures was benefi-
cial for developmental outcome and seizure control [10].
Moreover, Chung et al. reported that the group of
TSC patients diagnosed prior to seizures had lower per-
centage of refractory seizures and lower number of
trailed antiepileptic drugs despite the fact that none of
those children had a regular surveillance EEG as in our
previous study [33]. Furthermore, the prevalence of se-
vere developmental disability was also significantly lower
[33]. The explanation of those data is that considering
the awareness of the association between seizures and
developmental outcome parents were probably earlier
educated about seizures recognition and clinicians vigi-
lance was also greater in patients diagnosed before sei-
zures [33]. Consequently,seizures had been noticed and
antiepileptic drugs had been implemented earlier, which
increased a chance for better seizure control and im-
proved the clinical outcome [10, 12, 13, 17, 33].
Therefore, as children diagnosed with TSC before seiz-
ure onset have better prognosis [10, 13, 33] it needs to
be emphasized that early TSC diagnosis is becoming piv-
otal and should be established as soon as possible.
Although our study group represents less than a half
of TSC population from our clinics born between 1990
and 2016 (20% from the Department of Neurology and
Epileptology of The Children’s Memorial Health Institute
of Warsaw and 13% from the Child Neuropsychiatry Unit
and Epilepsy Center of the San Paolo Hospital in Milan),
we observed that the number of children referred before
4 months of life significantly increased in recent years. It
is probably due to the increased awareness of obstetri-
cians, neonatologists and pediatricians. In the EPISTOP
study we are collaborating with pediatricians, child cardi-
ologist, neonatologist and obstetrician from different med-
ical centers and emphasizing the importance of early
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recognition of TSC signs and referral children for further
diagnosis.
In Fig. 1 we propose the diagnostic and management
algorithm for early TSC diagnosis. Especially obstetri-
cians, neonatologists and pediatricians could benefit
from this flowchart, as they are usually the first physi-
cians who take care of newborns and infants with sus-
pected TSC.
If TSC is suspected prenatally, mother should be re-
ferred to maternal fetal medicine to perform fetal brain
MRI. If the TSC diagnosis is prenatally confirmed, child
should be referred preferably to TSC centre/specialist
just after birth and all recommend studies should be
conducted [34]. If the TSC centre/specialist is not avail-
able, the patient should be under the care of multidiscip-
linary pediatric centre. Moreover, regular EEG monitoring
every 4 weeks needs to be commence since birth.
Parents should be aware and educated about the risk
and recognition of seizures and genetic counseling
need to be provided.
If TSC is not confirmed prenatally or a child is sus-
pected of having TSC after birth, all diagnostic tests
should be performed as soon as possible preferably in
TSC centre. A brain MRI is one of the most useful tests
in early TSC diagnosis, detecting pathological lesions in
the vast majority of patients, and should be performed
preferably within the first 6 weeks of life. Although the
turnaround time of genetic analysis can be long in some
countries, DNA testing is a useful tool to confirm the
diagnosis of TSC and should be also requested as soon
as possible, especially in the absence of sufficient clinical
signs. Due to the design of the study all our patients had
cardiac tumors. However, as CRs are a frequent sign of
TSC, especially in infants, echocardiography may also fa-
cilitate the diagnosis in patients suspected of the disease
and should be early performed. Skin examination with
Wood’s lamp is helpful in identifying hypomelanotic
macules. It is also an easy and cheap test, and should be
performed in every patient during each visit. We also
recommend an early ophthalmological consultation and
abdominal ultrasonography or MRI in patients suspected
of having TSC in the absence of other signs or when
brain MRI cannot be performed early.
Limitations of the study
Some limitations of the study should be acknowledged.
It is a retrospective study and we did not analyze the
data of seizure onset and developmental outcome in our
cohort. However, we provide the literature data about
the improved prognosis of children diagnosed prior to
seizures. Moreover, we included in this study only chil-
dren in whom the first sign of the disease was cardiac
tumor/s. However, early diagnosis of TSC could also be
made in patients without cardiac tumors, although it
might be more challenging. Nevertheless, in recent years
most children have been referred to our clinics in in-
fancy with suspected TSC based on the presence of sin-
gle or multiple cardiac tumors. Therefore, we believe
Fig. 1 Diagnostic algorithm for early TSC diagnosis and management in infants. In patients suspected for TSC the diagnostic studies should be
performed early, as soon as possible. Ordinal numbers in diagnostic studies for patients with possible TSC indicate the importance and priority of
those studies for early TSC diagnosis. However, it is recommended to perform all the tests
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that this study will contribute to the earlier diagnosis of
TSC, allowing the early introduction of EEG monitoring
and antiepileptic treatment with a view to the improve-
ment of neurodevelopmental outcome.
Conclusions
Early diagnosis of TSC before seizure onset is feasible,
and - in the light of recent studies and recommendations
[10, 11, 13, 17–19, 33] - it is becoming pivotal for epi-
lepsy management with possible improvement of the
clinical outcome. Early TSC diagnosis is mostly based on
clinical signs. Brain MRI, echocardiography and careful
skin examination with Wood’s lamp should be per-
formed early in every young patient suspected of having
TSC. Genetic testing for TSC1/2 mutations should also
be conducted early, when possible. However, as in most
cases the turnaround time is long and in some patients
the mutation is not found, clinical studies for TSC signs
remain the most substantial for early TSC diagnosis and
cannot be abandoned.
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